Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group

What Was Tested

Researchers studied BNP (Nesiritide) and ANP (Atrial Natriuretic Peptide) in this randomized controlled trial publication.

The researchers investigated the clinical use of nesiritide in such patients.

Who Took Part

According to the abstract, 127 patients were involved.

PubMed indexes the participants as middle-aged adults, both men and women.

In the comparative trial, which did not require hemodynamic monitoring, 305 patients were randomly assigned to open-label therapy with standard agents or nesiritide for up to seven days.

How the Study Was Run

The researchers set it up as a randomized, double-blind, open-label and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got BNP (Nesiritide) and who got the comparison, which limits bias.

As a double-blind BNP (Nesiritide) study, the assignments were hidden from both participants and investigators until the end.

Being open-label, the BNP (Nesiritide) study did not mask who received what.

A placebo (an inactive look-alike) gave the BNP (Nesiritide) group a baseline to be compared against.

What Was Measured

The subject headings attached to it are Atrial Natriuretic Factor, Cardiotonic Agents, Dyspnea, Fatigue, Heart Failure, Hypotension and Natriuretic Peptide, Brain.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of BNP (Nesiritide) and ANP (Atrial Natriuretic Peptide) in 127 patients.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2000 (The New England journal of medicine), a journal based in United States.

More context: the BNP (Nesiritide) compound page and the ANP (Atrial Natriuretic Peptide) compound page, all human trials.